Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd. is a technology-powered biopharmaceutical company dedicated to the discovery, development, and commercialization of specialty medicines globally, with a particular focus on Japan and the broader Asia-Pacific region. Headquartered in Tokyo, Japan, the company's mission is to accelerate the development of life-changing medicines through significant investment in science and technology.

At the core of Nxera Pharma's operations is its proprietary NxWave™ platform, which leverages G Protein Coupled Receptor (GPCR) targeted structure-based drug design to identify novel small molecules, peptides, and therapeutic antibodies. The company's extensive pipeline, comprising over 30 active programs, targets areas of high unmet medical need, including neurology, gastrointestinal and immunological disorders, metabolic diseases, and rare diseases. Nxera Pharma also commercializes products such as PIVLAZ® for cerebral vasospasm and QUVIVIQ® for insomnia, particularly in the Japanese market.

Formerly known as Sosei Group Corporation or Sosei Heptares, the company officially rebranded to Nxera Pharma on April 1, 2024, unifying its global operations under a single identity. Led by President and CEO Chris Cargill, Nxera Pharma is strategically positioned to combine advanced drug discovery with commercial execution. The company reported strong financial performance in Q1 2026, with increased revenue and operating profit, and is focused on achieving profitability by 2030 through streamlined operations and a reprioritized pipeline, emphasizing next-generation therapies for obesity, metabolic, and endocrine disorders.